Vise Technologies Inc. Buys 6,827 Shares of Eli Lilly and Company $LLY

Posted by Brenda Bartman on Nov 2nd, 2026

Eli Lilly and Company logo Vise Technologies Inc. raised its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 19.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 41,180 shares of the company’s stock after buying an additional 6,827 shares during the quarter. Vise Technologies Inc.’s holdings in Eli Lilly and Company were worth $47,648,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of LLY. Investment Partners LTD. boosted its holdings in Eli Lilly and Company by 28.6% in the third quarter. Investment Partners LTD. now owns 7,314 shares of the company’s stock worth $8,463,000 after acquiring an additional 1,627 shares in the last quarter. Intrua Financial LLC increased its holdings in shares of Eli Lilly and Company by 0.6% during the third quarter. Intrua Financial LLC now owns 2,257 shares of the company’s stock valued at $2,612,000 after acquiring an additional 13 shares in the last quarter. BNB Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 4.1% during the third quarter. BNB Wealth Management LLC now owns 641 shares of the company’s stock valued at $741,000 after acquiring an additional 25 shares in the last quarter. Summit Global Investments raised its position in shares of Eli Lilly and Company by 18.9% in the 3rd quarter. Summit Global Investments now owns 12,376 shares of the company’s stock valued at $14,319,000 after purchasing an additional 1,969 shares during the last quarter. Finally, Invera Wealth Advisors LLC raised its holdings in shares of Eli Lilly and Company by 16.1% in the third quarter. Invera Wealth Advisors LLC now owns 1,812 shares of the company’s stock worth $2,097,000 after buying an additional 251 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,415.64 on Monday. The business’s 50-day moving average is $1,197.72 and its two-hundred day moving average is $1,092.57. The company has a market capitalization of $1.33 trillion, a P/E ratio of 45.95, a P/E/G ratio of 1.80 and a beta of 0.40. Eli Lilly and Company has a fifty-two week low of $834.19 and a fifty-two week high of $1,449.68. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter in the previous year, the firm posted $7.02 EPS. The company’s revenue for the quarter was up 38.6% on a year-over-year basis. Research analysts predict that Eli Lilly and Company will post 35.18 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s payout ratio is presently 22.46%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by company insiders.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Wall Street Analyst Weigh In

LLY has been the topic of several research reports. UBS Group reissued a “buy” rating and issued a $1,625.00 target price on shares of Eli Lilly and Company in a research report on Friday. HSBC lifted their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. Truist Financial reiterated a “buy” rating and set a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday. Morgan Stanley raised their price objective on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Argus raised their price objective on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,398.43.

View Our Latest Research Report on Eli Lilly and Company

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.